Related Experiment Videos
Donor bone marrow response to immunosuppressive treatment
R Arranz1, N González, D Fernández-Garese
1Servicio de Hemotologia, Hospital de la Princesa, Madrid, España.
Acta Haematologica
|January 1, 1988
Summary
Aplastic anemia recurrence after bone marrow transplant was managed with immunosuppressive therapy. Continuous ciclosporin A treatment is currently needed to maintain donor hematopoiesis, suggesting an ongoing immune-related mechanism.
Area of Science:
- Hematology
- Immunology
- Transplantation
Background:
- Idiopathic severe aplastic anemia in an 8-year-old male treated with allogeneic bone marrow transplantation.
- Successful initial engraftment followed by recurrence of severe aplastic anemia after 3 years.
Observation:
- Second bone marrow transplantation was not feasible.
- Alternative immunosuppressive treatments were administered sequentially.
Findings:
- Antithymocyte globulin, antithymocyte globulin plus ciclosporin A, and ciclosporin A alone provided transient responses.
- Uninterrupted ciclosporin A treatment is currently required to maintain normal donor hematopoiesis.
Implications:
- Suggests an immune-related and persistent pathogenic mechanism underlying the aplastic recurrence.
- Highlights the need for continuous immunosuppression in managing refractory aplastic anemia.
- Demonstrates the potential role of ciclosporin A in maintaining hematopoiesis in relapsed cases.